New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against mycobacterium tuberculosis

26Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

Abstract

In an effort to discover new drugs to treat tuberculosis (TB) we chose alanine racemase as the target of our drug discovery efforts. In Mycobacterium tuberculosis, the causative agent of TB, alanine racemase plays an essential role in cell wall synthesis as it racemizes L-alanine into D-alanine, a key building block in the biosynthesis of peptidoglycan. Good antimicrobial effects have been achieved by inhibition of this enzyme with suicide substrates, but the clinical utility of this class of inhibitors is limited due to their lack of target specificity and toxicity. Therefore, inhibitors that are not substrate analogs and that act through different mechanisms of enzyme inhibition are necessary for therapeutic development for this drug target.

Cite

CITATION STYLE

APA

Anthony, K. G., Strych, U., Yeung, K. R., Shoen, C. S., Perez, O., Krause, K. L., … Koski, R. A. (2011). New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against mycobacterium tuberculosis. PLoS ONE, 6(5). https://doi.org/10.1371/journal.pone.0020374

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free